Novel opportunities for thymidylate metabolism as a therapeutic target

For over 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) has remained the central agent in therapeutic regimens employed in the treatment of colorectal cancer and is frequently combined with the DNA-damaging agents oxaliplatin and irinotecan, increasing response rates and improving overall surv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2008-09, Vol.7 (9), p.3029-3037
Hauptverfasser:	Wilson, Peter M, Fazzone, William, LaBonte, Melissa J, Deng, Jinxia, Neamati, Nouri, Ladner, Robert D
Format:	Artikel
Sprache:	eng
Schlagworte:	5-fluorouracil Adenocarcinoma - enzymology Adenocarcinoma - pathology Antineoplastic Agents - pharmacology Breast Neoplasms - enzymology Breast Neoplasms - pathology Cell Line, Tumor colorectal cancer Computational Biology DNA Damage Drug Design Drug Resistance, Neoplasm - drug effects dUTPase fluoropyrimidine Fluorouracil - pharmacology Humans Immunohistochemistry Pyrophosphatases - antagonists & inhibitors Reproducibility of Results Thymidine - metabolism uracil
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!